The US FDA is moving up the timeline for pediatric studies of systemic treatments for atopic dermatitis.
Sponsors should begin pediatric studies "typically after obtaining initial evidence of efficacy and safety from early phase studies in adults"...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?